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Radioimmunotherapy (RIT) with anti-CD123 monoclonal antibody CSL360 modiﬁed with nuclear
translocation sequence (NLS) peptides and labeled with the Auger electron-emitter, 111In
(111In-NLS-CSL360) was studied in the prevalent NOD/SCID mouse AML engraftment assay. Signiﬁcant
decreases in CD123þ leukemic cells and impairment of leukemic stem cell self-renewal were achieved
with high doses of RIT. However, NOD/SCID mice were very radiosensitive to these doses. At low non-
toxic treatment doses, 111In-NLS-CSL360 demonstrated a trend towards improved survival associated
with decreased spleen/body weight ratio, an indicator of leukemia burden, and almost complete era-
dication of leukemia from the bone marrow in some mice.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute myeloid leukemia (AML) remains a hematologic malig-
nancy with poor outcome and a high risk for relapse believed to be
caused by the survival of leukemic stem cells (LSCs), which are
responsible for disease repopulation following treatment [1]. This
important implication of LSCs was determined in in vivo assays
that allowed engraftment of primary AML specimens into the bone
marrow (BM) and spleen of immunocompromised mice. In the
non-obese diabetic/severe combined immunodeﬁcient (NOD/
SCID) mouse, researchers determined that LSCs have the ability to
self-renew and the capacity to proliferate and differentiate into
diverse leukemic cells [2,3]. Engraftment in the NOD/SCID mouse
has also been shown to correlate with poor response to che-
motherapy and overall poor patient survival [4,5] making it a
clinically predictive in vivo model. Based on the importance ofLtd. This is an open access article u
rmacy University of Toronto,
16 978 8511.
Reilly).LSCs, novel approaches that target these cells are being developed
and converging with the NOD/SCID mouse assay [6–9] in efforts to
advance desperately needed therapies into the clinic.
We have developed a novel radioimmunotherapy (RIT) strategy
targeting CD123 overexpressed on LSCs that we are evaluating in
the NOD/SCID mouse AML model. Indium-111 (111In) labeled to
CSL360 (CSL Limited, Parkville, Australia), a chimeric IgG1 speciﬁc
for CD123, was used to deliver Auger electron irradiation to LSCs.
111In emits nanometer–micrometer range Auger electrons, which
are highly toxic when delivered in close proximity to the DNA [10].
We previously observed that the modiﬁcation of anti-CD123 an-
tibodies with peptides [CGYGPKKKRKVGG] that harbor a nuclear
localization sequence (NLS; underlined) is able to deliver Auger
electrons to the nucleus of CD123þ AML cells and cause signiﬁcant
cytotoxicity in vitro [11]. In addition to Auger electrons, 111In emits
γ-photons used for imaging and we previously reported that
111In-NLS-CSL360 accumulated speciﬁcally at sites of AML en-
graftment in the BM and spleen of NOD/SCID mice, permitting
disease visualization by microSPECT/CT [12]. In order to in-
vestigate the potential of 111In-NLS-CSL360 as a RIT agent for AML,
we describe here the results of initial studies to examine its effectsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Effect of treatment of NOD/SCID mice engrafted with AML specimen 090295 with radioimmunoconjugates (17–18 MBq; 20–27 μg) on leukemic cells in the bone
marrow (BM). (A) Percentage of human hCD45þ/CD123þ cells in the BM of primary engrafted mice at 8 weeks. Data shown for untreated mice was taken from reference 12.
(B) Percentage of hCD45þ cells in the BM of secondary recipient mice engrafted with donor cells from primary AML-engrafted mice treated with radioimmunoconjugates.
(C) Percentage of hCD45þ/CD34þ progenitor cells in the BM of recipent mice. (D) Percentage of hCD45þ/CD34þ/CD38- stem cells in the BM of recipient mice. Bars represent
the mean7SD and values for individual mice are shown. Signiﬁcant differences (Po0.05) are indicated by an asterisk.
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model.2. Materials and methods
Radioimmunoconjugates were prepared as previously reported
[12]. Primary AML specimens were collected under a protocol (01–
0573-C) approved by the Research Ethics Board of the University
Health Network (UHN). Sublethally irradiated (200 cGy) NOD/SCID
mice were intravenously (i.v.) inoculated within 12 h with 5106
cells from BM specimens from AML patients (specimens 090295and 080179). All animal studies were conducted under a protocol
(864.5) approved by the Animal Care Committee at the UHN fol-
lowing Canadian Council on Animal Care (CCAC) guidelines.
Three RIT studies were performed. In the ﬁrst study, groups of
5 mice with nearly complete leukemic repopulation of the BM at
8 weeks post-engraftment with specimen 090295 were injected
intravenously with 16.771.3 MBq of 111In-NLS-CSL360 or
18.370.8 MBq of irrelevant 111In-NLS-isotype control chimeric
IgG1 (111In-NLS-chIgG1) and microSPECT/CT imaging of AML en-
graftment was performed as reported [12]. The mass of radio-
immunoconjugates injected was 20–27 μg. The effect on human
(h)CD45þ/CD123þ leukemia cells in the BM was measured
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The repopulating capacity of BM cells was studied by inoculating
3.75104 viable donor cells from treated mice into groups of
5 recipient NOD/SCID mice. After 8 weeks, the BM from recipient
mice was analyzed for hCD45þ cells, hCD45þ/CD34þ progenitor
cells and hCD45þ/CD34þ/CD38- stem cells. In a second study,
groups of 5–7 mice with leukemia engrafted at one week post-
inoculation with specimen 080179 were treated with
111In-NLS-CSL360 (4.570.2 MBq), 111In-CSL360 (4.9 7 0.1 MBq),
111In-NLS-chIgG1 (4.4 7 0.1 MBq) or received no treatment. The
mass of radioimmunoconjugates injected was 13–15 μg. The BM
was analyzed at 8 weeks for leukemic engraftment. In the third
study, groups of 4–5 NOD/SCID mice were inoculated with
2.5105 CD34þ/CD38/CD123þ sorted cells from specimen
080179. At 48 h post-inoculation, mice were treated with
111In-NLS-CSL360 (2.370.0 MBq), 111In-CSL360 (2.970.2 MBq),
111In-NLS-IgG1 (2.270.0 MBq), or received no treatment. The mass
of radioimmunoconjugates administered was 5–10 μg. The survi-
val up to 180 days was determined. At the time of death or at the
completion of the study, the spleen/body weight ratio was
measured.
Finally, the effects of 111In-NLS-CSL360 on hematopoietic
function in healthy Balb/c mice was studied. Groups of 2–4 mice
were injected i.v. with 6.171.4 MBq, 18.871.5 MBq or
35.870.9 MBq of 111In-NLS-CSL360 or an equivalent mass (70 μg)
of unlabeled CSL360 or received normal saline. At two weeks post-
treatment, a complete blood cell count (CBC) was obtained and
hemoglobin (Hb) levels were measured.
Signiﬁcant differences (Po0.05) for all studies were tested
using an unpaired, two-sided Student's t-test, 1-way ANOVA fol-
lowed by a Bonferroni multiple comparisons post-test, or log-rank
test.3. Results and discussion
3.1. CD123-targeted Auger electron radiation impairs LSCs in vivo
Specimen 090295 almost completely repopulated the NOD/SCID
mouse BM after 8-weeks reaching hCD45þ/CD123þ engraftment
levels of 84.7%73.5% [12]. This efﬁciently and reproducibly-en-
grafting AML specimen serves as a robust initial challenge to provide
insight on the efﬁcacy of a LSC-targeted Auger electron RIT approach.
A single dose of radioactivity (16–19 MBq; 20–27 μg) administered
per mouse of 111In-NLS-CSL360 was potent after only 72 h.
111In-NLS-CSL360 treatment resulted in a 1.8-fold reduction in the
engraftment of hCD45þ/CD123þ cells in the BM compared to mice
injected with 111In-NLS-chIgG1 (47.2%77.7% vs. 82.6%71.8%, re-
spectively; Po0.0001; Fig. 1A). This result is encouraging as a rapid
molecular response to treatment in AML patients is a favorable
characteristic associated with good outcome [13]. These results were
supported by biodistribution studies which showed 3-fold greater
uptake of 111In-NLS-CSL360 than 111In-NLS-chIgG1 in the femurs
which included the BM [8.873.2 vs. 3.070.3 percent injected dose/
g (%ID/g); P¼0.004] and 2-fold greater spleen uptake (24.173.2 vs.
13.872.3%ID/g; P¼0.004) [12]. These are known sites of engraft-
ment of AML in the NOD/SCID mouse. To test the effect on the re-
population capacity of LSCs, transplantations in secondary NOD/SCID
mice were conducted. 111In-NLS-CSL360 could reduce the leukemic
hCD45þ engraftment by a factor of 4.3 after 8 weeks compared to
mice treated with 111In-NLS-chIgG1 (Fig. 1B; P¼0.04). The proportion
of hCD45þ/CD34þ progenitor cells in the BM was signiﬁcantly de-
creased by 12-fold (Fig. 1C; P¼0.03). A 3.3-fold lower proportion of
cells occurred in the hCD45þ/CD34þ/CD38 cell fraction in the BM
of 111In-NLS-CSL360 treated mice compared to 111In-NLS-chIgG1
treated mice (Fig. 1D). Under these conditions, the NOD/SCID mouseassay was useful to monitor a rapid (72 h) treatment response to
111In-NLS-CSL360 and secondary transplantations demonstrated im-
pairment of LSCs. We next determined if non-irradiated and non-
engrafted NOD/SCID mice could tolerate similar doses of
111In-NLS-CSL360 (17–19 MBq; 21–24 μg) to evaluate long-term AML
disease. All mice exhibited decreased body weight and had to be
sacriﬁced by day 21. Engraftment of AML into NOD/SCID mice has
been instrumental in understanding leukemia biology but these mice
have a defect in DNA repair that makes them very sensitive to ra-
diation [14] and we demonstrate how this limitation of the NOD/
SCID assay poses a challenge to assess RIT approaches.
3.2. Effect of 111In-NLS-CSL360 on long-term AML disease progres-
sion and survival
To examine the longer term anti-leukemic effects of RIT, we
treated NOD/SCID mice engrafted with AML specimen 080179
with a single lower non-toxic dose of 111In-NLS-CSL360
(4.570.2 MBq; 13–15 μg). Specimen 080179 engrafts reproducibly
and aggressively into the BM of NOD/SCID mice and produces
increased levels of leukemic blasts in the blood and impairment of
normal murine hematopoiesis by week 8 [12]. Analysis of the BM
at 8 weeks revealed that in 1/5 mice 111In-NLS-CSL360 decreased
the proportion of hCD45þ cells compared to untreated mice by 10-
fold to o10% and the mean proportion of hCD45þ cells in all
5 mice was moderately decreased by 23.5% relative to 111In-CSL360
and 111In-NLS-chIgG1 (Fig. 2A). No mice treated with 111In-CSL360
(without NLS) or irrelevant 111In-NLS-chIgG1 exhibited decreased
hCD45þ cells in the BM. 111In-NLS-CSL360 signiﬁcantly reduced
the proportion of CD34þ/CD38/CD123þ LSCs in the BM by 2.1-
fold (Po0.01) compared to untreated mice. This ﬁnding suggests
that Auger electron RIT with 111In-NLS-CSL360 impairs LSC long
term survival and the NOD/SCID mouse assay is suitable to
monitor this effect at reduced doses. However, the dose of radio-
activity employed in these experiments most likely was in-
sufﬁcient to completely eradicate LSCs, which have inherent re-
sistance properties to radiation [15] and overexpression of pro-
teins involved in DNA repair [16].
The survival of NOD/SCID mice engrafted with sorted CD34þ/
CD38/CD123þ cells from specimen 080179 was evaluated follow-
ing treatment with reduced doses of 111In-NLS-CSL360 (2–3 MBq (5–
10 μg). There was a trend towards longer survival in mice treated
with 111In-NLS-CSL360 compared to mice receiving 111In-CSL360 or
untreated mice (median survival of 125, 110 and 95 days, respec-
tively; Fig. 3A). The median survival of mice treated with
111In-NLS-chIgG1 was similar to that for 111In-NLS-CSL360 treated
mice, possibly indicating a beneﬁcial effect of non-targeted radiation.
Because the spleen is also an organ for leukemic cell engraftment,
which is characterized by gross splenomegaly [11], we evaluated the
leukemic burden by determining the spleen/body weight ratio. All
radioimmunoconjugates decreased the spleen/body weight ratio
compared to untreated engrafted mice (Fig. 3B). This was not com-
pletely unexpected as the NOD/SCID mouse exhibits very low cir-
culating immunoglobulin levels which cause non-speciﬁc seques-
tration of human IgG1 by Fc receptors on spleen cells [11]. This would
cause leukemia cells to be irradiated by splenic accumulation of
111In-NLS-chIgG1. Nonetheless, there was a trend towards lower
spleen/body weight ratios in mice treated with 111In-NLS-CSL360.
The spleen/body weight ratios were 2.9-, 2.3 and 1.8-fold lower
compared to untreated AML-engrafted mice for 111In-NLS-CSL360,
111In-CSL360 and 111In-NLS-chIgG1, respectively. The spleen/body
weight ratio was increased by 15-fold in mice engrafted with AML
compared to sublethally irradiated but non-engrafted mice, demon-
strating splenomegaly associated with leukemia involvement. In
mice treated with 111In-NLS-CSL360, analysis of the BM of the two
surviving mice showed only 0.04% and 0.03% hCD45þ cells, whereas
Fig. 2. Effect of treatment of NOD/SCID mice engrafted with AML specimen 080179 with radioimmunoconjugates (4–5 MBq; 13–15 μg) on leukemic cells in the bone marrow
(BM). (A) Percentage of human hCD45þ cells. (B) Percentage of human CD34þ/CD38/CD123þ stem cells. Bars represent the mean7SD and values for individual mice are
shown. Signiﬁcant differences (Po0.05) are indicated by an asterisk.
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86.9% hCD45þ cells in their BM. The percentage of hCD45þ cells in
the BM for untreated AML-engrafted mice ranged from 65.6% to
81.6%. These results are encouraging because they demonstrate that
leukemia in mice inoculated with a high number (2.5105 cells/
mouse) of CD123þ LSCs could still be targeted and impaired by a
single low radioactivity dose of 111In-NLS-CSL360 and in two cases,
was almost completely eradicated from the BM.
111In-NLS-CSL360 decreased white blood cell (WBC) counts in
healthy Balb/c mice only at the highest dose administered
(35.870.9 MBq; P¼0.05) with no signiﬁcant effects compared to
mice injected with normal saline at lower doses (Table 1). Platelet
(PLT) counts were only modestly but not signiﬁcantly decreased atFig. 3. (A) Kaplan–Meier survival curve for NOD/SCID mice engrafted with CD34þ
immunoconjugates (2–3 MBq; 5–10 μg). (B) Effect of treatment with radioimmunoconju
spleen/body weight ratios for sublethally-irradiated but non-engrafted NOD/SCID mice a
for individual mice are shown. Signiﬁcant differences (Po0.05) are indicated by an astan intermediate dose (18.870.9 MBq; P¼0.10) but exhibited a
signiﬁcant and major decrease at the highest dose (Po0.001).
Only the highest dose of 111In-NLS-CSL360 signiﬁcantly reduced
hemoglobin (Hb) levels (P¼0.03) but there were no signiﬁcant
effects on RBC counts at any dose. An equivalent mass of unlabeled
CSL360 (70 μg) exhibited no effects on hematopoietic function.
Thus, doses of 111In-NLS-CSL360 up to 19 MBq (70 μg) were safely
administered to Balb/c mice whereas similar doses (17–19 MBq;
21–24 μg) were not tolerated by NOD/SCID mice as discussed, due
to the defect in DNA repair [14].
Auger electron RIT with 111In-NLS-CSL360 offers an unexplored
opportunity to speciﬁcally deliver ionizing radiation to the critical
LSC population in AML. Despite the power of the NOD/SCID mouse/CD38/CD123þ sorted cells from specimen 080179 and treated with radio-
gates on the spleen/body weight ratio at the study end-point. Also shown are the
nd engrafted mice receiving no treatment. Bars represent the mean7SD and values
erisk.
Table 1
Effect of 111In-NLS-CSL360 on hematopoietic function in healthy Balb/c mice.
Parametera Normal saline Unlabeled CSL360 111In-NLS-CSL360
70 μg 6.171.4 MBq 18.871.5 MBq 35.870.9 MBq
RBC Count (103/μL) 7.770.9 8.470.5 8.270.4 7.470.5 6.470.0
WBC Count (106/μL) 7.671.5 9.371.6 8.271.8 5.473.0 2.970.7b
PLT Count (103/μL) 72976 735743 7257122 4867150 150713b
Hb (g/dL) 11.670.6 12.470.6 12.170.5 11.070.6 9.270.1b
a Abbreviations: RBC: red blood cells; WBC: white blood cells; PLT: platelets; Hb: hemoglobin. Values represent the mean 7 SD (n¼2-4).
b Signiﬁcantly different (Po0.05) compared to mice injected with normal saline.
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kemia, there are major challenges for utilizing NOD/SCID mice to
study RIT due to its high sensitivity to radiation and low im-
munoglobulin levels which perturb the pharmacokinetics of
radiolabeled antibodies. Nonetheless, our results reveal an effect of
111In-NLS-CSL360 on decreasing leukemic cells in the BM of AML-
engrafted NOD/SCID mice, particularly the CD123þ cell sub-
population. Studies are in progress to optimize the dose of
111In-NLS-CSL360 and further evaluate its effectiveness and nor-
mal tissue toxicity for RIT of AML in both NOD/SCID mice and in
NOD Rag1null IL2rγ null (NRG) mice which have fully functional
DNA repair capacity [17].Conﬂict of interest
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